Antifungal susceptibility testing in Aspergillus spp. according to EUCAST methodology

被引:49
作者
Lass-Floerl, C.
Cuenca-Estrella, M.
Denning, D. W.
Rodriguez-Tudela, J. L.
机构
[1] Univ Innsbruck, Dept Hyg & Clin Microbiol, A-6020 Innsbruck, Austria
[2] Univ Manchester, Sch Med, Manchester M13 9PL, Lancs, England
[3] Univ Manchester, Fac Life Sci, Manchester M13 9PL, Lancs, England
关键词
susceptibility tests; EUCAST; resistance; Aspergillus;
D O I
10.1080/13693780600779401
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The availability of new antifungal agents has multiplied the demand for in vitro antifungal susceptibility testing for Aspergillus spp. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) has charged its Antifungal Susceptibility Testing Subcommittee (AFST-EUCAST) with the preparation of new guidelines for in vitro susceptibility testing of antifungals against Aspergillus spp (EUCAST-AST-ASPERGILLUS). This committee has modified the reference method for broth dilution antifungal susceptibility testing of filamentous fungi (M38-A) as follows: (i) RPMI 1640 supplemented with 2% glucose (RPMI 2%G) as assay medium, (ii) inoculum preparation by conidium counting in a haemocytometer and (iii) an inoculum. size of 2 x 10(5) -5 x 10(5) CFU/ml. The incubation time is about 48 h at 35 degrees C and MIC is read visually. The MIC value is a no-growth visual endpoint. The standard method described herein is intended to provide a valid and economic method for testing the susceptibility to antifungal agents of Aspergillus spp., to identify resistance, and to facilitate an acceptable degree of conformity, e.g. agreement within specified ranges and between laboratories in measuring the susceptibility.
引用
收藏
页码:S319 / S325
页数:7
相关论文
共 55 条
[1]   Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi [J].
Aberkane, A ;
Cuenca-Estrella, M ;
Gomez-Lopez, A ;
Petrikkou, E ;
Mellado, E ;
Monzón, A ;
Rodriguez-Tudela, JL .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (05) :719-722
[2]   Conidial viability assay for rapid susceptibility testing of Aspergillus species [J].
Balajee, SA ;
Marr, KA .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (08) :2741-2745
[3]   FUNGAL-INFECTIONS IN CANCER-PATIENTS - AN INTERNATIONAL AUTOPSY SURVEY [J].
BODEY, G ;
BUELTMANN, B ;
DUGUID, W ;
GIBBS, D ;
HANAK, H ;
HOTCHI, M ;
MALL, G ;
MARTINO, P ;
MEUNIER, F ;
MILLIKEN, S ;
NAOE, S ;
OKUDAIRA, M ;
SCEVOLA, D ;
VANTWOUT, J .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1992, 11 (02) :99-109
[4]   Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma [J].
Chen, J ;
Li, HM ;
Li, RY ;
Bu, DF ;
Wan, Z .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (01) :31-37
[5]   In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. Acquired resistance to itraconazole [J].
Chryssanthou, E .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1997, 29 (05) :509-512
[6]   In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole [J].
Dannaoui, E ;
Persat, F ;
Monier, MF ;
Borel, E ;
Piens, MA ;
Picot, S .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (04) :553-555
[7]   Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis [J].
Denning, DW ;
Ribaud, P ;
Milpied, N ;
Caillot, D ;
Herbrecht, R ;
Thiel, E ;
Haas, A ;
Ruhnke, M ;
Lode, H .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :563-571
[8]   Itraconazole resistance in Aspergillus fumigatus [J].
Denning, DW ;
Venkateswarlu, K ;
Oakley, KL ;
Anderson, MJ ;
Manning, NJ ;
Stevens, DA ;
Warnock, DW ;
Kelly, SL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1364-1368
[9]   Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection [J].
Denning, DW ;
Radford, SA ;
Oakley, KL ;
Hall, L ;
Johnson, EM ;
Warnock, DW .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (03) :401-414
[10]   Therapeutic outcome in invasive aspergillosis [J].
Denning, DW .
CLINICAL INFECTIOUS DISEASES, 1996, 23 (03) :608-615